The crude survival rate in this group of patients has been 74 % (39 deaths). For Stage I disease the survival rate over the entire period studied is 89-4%. Stage II disease presents a more serious prognosis with a crude survival rate of 47-3%. A group of 73 has been followed up for 5 years or more from the time of endolymphatic therapy. These patients represent the early treatment group when the isotopes used were principally radioactive gold 198Au or 1311. The five-year survival rate is 80 % for Stage I disease and 20 % for Stage II disease. It is hoped that these Stage IL figures will have improved with the increased use of 32P-lipiodol. However, even when analysing the results of 13ll-lipiodol in Stage II disease it is realized that the bad results are not due to ineffectiveness in treating the localized disease in lymph nodes. This was successful but patients died from systemic disease which must have been occult at the time of the initial treatment. In other words, the disease was already a systemic problem at the time of treatment.
Dr G A Currie (Chester Beatty Research Institute, Belmont, Sutton, Surrey)
Effect ofAutoimmunization with Irradiated Tumour Cells on Specific Cell-mediated Immunity in Patients with Malignant Melanoma
Recent progress in the study of animal tumours has encouraged us to re-examine the possibilities of using immunological methods in the treatment of cancer. The possible value of autologous tumour cell vaccines as a form of specific active immunotherapy was first tested over 70 years ago and has been the subject of many clinical investigations in the intervening years (for review, see Southam 1961) . In all these series of patients, treated with a variety of immunization techniques, there has been no evidence of any beneficial clinical effects. However, all the patients so treated were suffering from advanced malignant disease. We now know that a vigorous immune response is only capable of dealing with a very limited number of syngeneic tumour cells and thus any method of active immunotherapy, when used as the only form of treatment, is unlikely to be of value in patients with advanced disease. It may, however, make a valuable contribution when combined with other, more vigorously cytoreductive forms oftreatment.
The presence of specific tumour-associated antigens is now well established in many expenmental rodent tumours (forreview, see Old & Boyse 1965) . In man the picture is less clear. Such antigens, and host reactions to them, have, however, been demonstrated in acute leukvemia (Fridman & Kourilsky 1969 ), Burkitt's lymphoma (Klein et al. 1967) , and malignant melanoma (Morton et al. 1968 ). In the serum of patients with malignant melanoma specific antitumour antibodies have been detected in the early stages of the disease (Lewis et al. 1969 ). These antibodies disappear from the peripheral blood as the disease progresses and are undetectable in the sera of cases with widespread dissemination. Autoimmunization with irradiated tumour cells in such patients may, however, provoke the transient reappearance of these antibodies (Ikonopisov et al. 1970) . The role of circulating humoral antibody in tumour immunity is unknown. Cell-mediated reactions are probably of greater significance. The lymphocyte appears to play a central role in these cell-mediated responses, and although cellular immunity is still poorly understood, the presence of specifically cytotoxic lymphocytes in animals immunized against syngeneic tumours has been demonstrated (Takasugi & Klein 1970) .
This communication will describe experiments designed to detect and quantitate the specific cytotoxic properties of peripheral blood lymphocytes when confronted in short-term tissue culture with autologous tumour cells in a series of patients with malignant melanoma. Some of the patients were then immunized against their own tumours and any subsequent changes in lymphocyte cytotoxicity assayed.
Experimental
The patients investigated in this study were seen at surgical and radiotherapy clinics at a specialized cancer hospital. They were consequently a somewhat selected series as most of them had some degree of metastatic spread either to regional lymph nodes, the skin or viscera. Fragments of melanoma were obtained at operation, placed in sterile tissue culture medium 199, transported directly to the laboratory and used immediately. The tumour fragments were trimmed, washed and then minced. The resultant cell suspension was then cultured.
Lymphocyte Cytotoxicity
The technique used for lymphocyte cytotoxicity was adapted from the microassay described by Takasugi & Klein (1970) . Briefly, the melanoma cells were grown in 10 VI microcultures for 24 hours, then the patients' lymphocytes were added to these cultures and incubated for 48 hours. The cultures were then inverted to allow the dead cells to detach from the plastic surface of the culture vessel and the culture was fixed and stained. The number of cells remaining in each well was counted. As each microplate contains 60 wells, it was possible to establish 60 replicate cultures. The dose of lymphocytes added to each well was varied to give a range of lymphocyte: tumour cell ratios from 300:1 downwards in doubling dilutions. Thus it was possible to calculate the percentage of cells killed by each given lymphocyte-target cell ratio and with this information a cytotoxicity dose-response curve was obtained for each patient.
Autoimmunization with Tumour Cells
Where sufficient numbers of tumour cells were available the patients were immunized with their own irradiated tumour cells. Cells were irradiated by a 60Co source and were given a total of 12-5 krad. Each patient received between 3 and 5 x 108 autologous melanoma cells by subcutaneous injection in at least five sites involving all the limbs.
Immunofluorescence
Patients' sera were also examined for antimelanoma antibodies by the immunofluorescence technique as previously described (Lewis et al. 1969) .
By examining the cytotoxic effect of lymphocytes on autologous tumour cells we are performing an uncontrolled experiment. What is the effect of normal lymphocytes? Unfortunately, this is an impossible situation except perhaps in the case of identical twins, as testing normal allogeneic lymphocytes could possibly involve reactions mediated by histocompatibility antigens as well as tumour antigens. However, we did attempt to investigate this point. Fig 1 shows the effect of lymphocytes from 12 normal individuals on melanoma cells; 11 of them had no toxic effect but one apparently normal individual possessed lymphocytes capable of destroying melanoma cells at extremely low lymphocytetumour cell ratios.
The effect of autologous lymphocytes on melanoma cells is shown in Fig 2, which demonstrates the effects of lymphocytes from 2 of the patients, one characteristically positive and the other negative.
TIwenty-five patients have been tested so far by this technique. Of these only 3 possessed lympho- cytes which could be called cytotoxic. Although the presence of such lymphocytes did not correlate with simple clinical staging of the disease, it may well have been related to tumour volume. The disease in these 3 patients was disseminated but at the time they were studied it was present only as minute skin nodules. Furthermore, there was no evidence of any correlation with the presence or absence of tumour-specific antibodies detected by immunofluorescence.
Twelve of the patients with noncytotoxic lymphocytes were then immunized with their own irradiated tumour cells and their lymphocytes studied at intervals thereafter. Fig 3 shows the cytotoxicity curve from a patient with melanoma before and 6 days after autoimmunization, and indicates that the immunization procedure had evoked the appearance of cytotoxic lymphocytes in the peripheral blood. Of the 12 patients so far studied in this way 5 have produced such cytotoxic lymphocytes. In the few cases we have been able to study, these cytotoxic cells are present at 7 and 14 days but have disappeared by 21 days. Again there was no clear-cut correlation between the development of such cells and the appearance of antibodies in the serum. There was no evidence that such serum antibodies or any other serum factor could inhibit the activity of the lymphocytes in vitro (see Fig 4) . The cytotoxicity of the lymphocytes appears to be specific to each individual tumour. We have been unable to demonstrate any cross-reactivity O ----0, a cytotoxic dose-response curve between different melanomas or between melanomas and other tumours.
The clinical appraisal of any form of therapy in malignant melanoma is notoriously difficult owing to the extremely variable course of the disease. However, we have no indication so far that the autoimmunization procedure has had any influence on the progress of the disease either good or bad. It has not cured anybody but it does not seem to have harmed anyone either.
Discussion
Other studies of cell-mediated immunity in advanced malignant disease in man have been described by Hellstr6m et al. (1968) . Their series included a few patients with melanoma and their results differ radically from ours. They claim to have detected cell-mediated immunity in all patients with advanced cancer and, furthermore, their tests revealed complete cross-reactions between tumours of similar histological type. That is, the lymphocytes from one patient with malignant melanoma would inhibit the growth of tumour cells cultured from all other cases of melanoma.
Their assay system involved the inhibition of growth of trypsinized subcultured tumour cells by a vast number of lymphocytes. It is perhaps possible that their technique and ours are exploring different antigen systems. We have shown in the past that there are two different types of tumour antigen in melanoma cells. First, there is a cross-reacting cytoplasmic group of antigens, and secondly, and probably more relevant to tumour immunology, there is a system of individual specific surface membrane antigens. I would like to suggest that the Hellstroms' technique may be looking at the former and ours at the latter. From studies of cellular immunity in tumour bearing animals it is perhaps surprising that cytotoxic lymphocytes can be found at all in the peripheral blood of any of the untreated patients. Alexander et al. (1967) have shown that the presence of a tumour specifically inhibits the propagation of cellular immunity beyond the regional draining lymph nodes. Only by total excision of the tumour or by autoimmunization with irradiated cells at distant sites involving previously unaffected lymph nodes can evidence of systemic cell-mediated immunity be produced.
The development in vitro of cytotoxic lymphocytes in the 5 cases who responded to their autograft was not associated with any clinically detectable killing of tumour cells in vivo. In other words, any contribution to tumour cell death caused by their newly acquired immune status is negligible when compared to the total tumour load with which the patient is confronted. Thus, if specific active immunotherapy is to be of clinical value in controlling tumours, it must be used as an adjunct to the more vigorously cytoreductive forms of treatment. Active immuniza- cell-mediated immune responses in some patients and it seems feasible that such a technique may prove to be of value as part of a combination therapeutic approach to cancer treatment.
